Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To imply that hedge funds are universally bad is the same as saying all people have the same degree of education and intelligence.
Quote:
--------------------------------------------------------------------------------
" today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital."
Google can be hard to use for some so here is a link right to their page: http://www.domcapllc.com/
DOMCAPLIC IS A HEDGE FUND!
--------------------------------------------------------------------------------
What Is a Hedge Fund
A hedge fund is a fund that can take both long and short positions, use arbitrage, buy and sell undervalued securities, trade options or bonds, and invest in almost any opportunity in any market where it foresees impressive gains at reduced risk. Hedge fund strategies vary enormously -- many hedge against downturns in the markets -- especially important today with volatility and anticipation of corrections in overheated stock markets. The primary aim of most hedge funds is to reduce volatility and risk while attempting to preserve capital and deliver positive returns under all market conditions.
There are approximately 14 distinct investment strategies used by hedge funds, each offering different degrees of risk and return. A macro hedge fund, for example, invests in stock and bond markets and other investment opportunities, such as currencies, in hopes of profiting on significant shifts in such things as global interest rates and countries’ economic policies. A macro hedge fund is more volatile but potentially faster growing than a distressed-securities hedge fund that buys the equity or debt of companies about to enter or exit financial distress. An equity hedge fund may be global or country specific, hedging against downturns in equity markets by shorting overvalued stocks or stock indexes. A relative value hedge fund takes advantage of price or spread inefficiencies. Knowing and understanding the characteristics of the many different hedge fund strategies is essential to capitalizing on their variety of investment opportunities.
It is important to understand the differences between the various hedge fund strategies because all hedge funds are not the same -- investment returns, volatility, and risk vary enormously among the different hedge fund strategies. Some strategies which are not correlated to equity markets are able to deliver consistent returns with extremely low risk of loss, while others may be as or more volatile than mutual funds. A successful fund of funds recognizes these differences and blends various strategies and asset classes together to create more stable long-term investment returns than any of the individual funds.
I know what I own and am years long AMBS
Re Dominion Capital, LLC, increasing their investment to (i.e., faith in) Amarantus.
Facts (as stated in the 1/31/13 PR):
In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000. The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed to a "no shorting" provision.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
Opinions that “undisclosed conditions” are included are baseless. For those wishing to review the facts reported in the 8-K of 11/14/12:
On 14 November 2012, Amarantus Biosciences, Inc. (the “Company”), entered into a Convertible Promissory Note with Dominion Capital, LLC, or its registered assigns (“Dominion”), in the principal amount of $600,000.00, payable in four tranches, with a Maturity Date of 3 June 2013.
The Note bears interest at the rate of ten (10%) percent per annum from 14 November until paid in full, and can be converted into common shares of the Company at a price of ten ($0.10) cents per share, subject to certain conditions to be met by the Company.
The coming days, weeks and months will reveal numerous events propelling AMBS to even greater success than that already achieved.
I know what I own and am years long AMBS
AMBS up 296% since 11/1/12. Not bad for three months, and the best is yet to come.
I know what I own and am years long AMBS
Time relative information should not be OMITTED when trying to cite "facts."
Post #54143 states:
Re Trading & PPS for the period 1/2/13 – 2/1/13:
Total share volume: 375,787,245 (daily average 17,081,238)
Total $ volume: $38,551,557 (daily average $1,752,344)
Total trades volume: 19054 (daily average 866)
Average shares traded/trade: 19,722
Average $ traded/trade: $2,023
Average PPS: .09804
Only 5 of 22 trading days had an average PPS above .10646.
Volume each of the past 7 days has been less than 8 M.
01/24/13 - 4,062,831
01/25/13 - 5,046,005
01/28/13 - 7,837,595
01/29/13 - 6,033,433
01/30/13 - 2,286,006
01/31/13 - 3,443,865
02/01/13 - 3,310,991
The float is all but locked up, and management has been working without compensation and also investing by buying additional shares. They are in it with each shareholder.
I know what I own and am years long AMBS
The Michael J. Fox Foundation (MJFF) does NOT invest in scams or disreputable companies. They have a comprehensive vetting process to ensure their grant monies are given to real companies and for real, viable research purposes.
Re MJFF Funding:
MJFF awards grants on THEIR schedule, not that of “investors.” With the upcoming MJFF Hot Topics Webinar on 2/19, the MJFF is preparing to provide organization updates. Click the following link for more info:
Hot Topics Webinar
I know what I own and am years long AMBS
Re Investing for Future purposes:
To say that a company who invests $3M in R&D (especially in the biopharm industry) LOST the money is akin to saying:
- a person making mortgage payments LOST their money every month because they do NOT own their house, or
- a person investing in a stock/company LOST their money immediately after buying the stock because they did NOT receive an immediate payout.
Intelligent investments for future gains/benefit are not “lost” money IMO.
I know what I own and am very long AMBS
Do these look like scams?
MJFF 2010 Grant Abstract
AMBS & Banyan Biomarkers Collaboration on TBI
Peer Reviewed Data
Isn't it amazing how these companies/professional organizations have been duped into buying into this "scam"? hahaha - NOT!
I know what I own and am years long AMBS
To imply that hedge funds are universally bad is the same as saying all people have the same degree of education and intelligence.
Average daily shares trading volume last 7 trading days: 4.57 M
Average daily $ trading volume last 7 trading days: $408,593
Float is in the hands of knowledgeable, well-informed and patient longs who know what they own.
Daily PPS action is immaterial at these trading volume levels, regardless of any opinions.
I know what I own and am years long AMBS
Re Dominion Capital, LLC, increasing their investment to (i.e., faith in) Amarantus.
Facts (as stated in the 1/31/13 PR):
In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000. The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed to a "no shorting" provision.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
Opinions that “undisclosed conditions” are included are baseless. For those wishing to review the facts reported in the 8-K of 11/14/12:
On 14 November 2012, Amarantus Biosciences, Inc. (the “Company”), entered into a Convertible Promissory Note with Dominion Capital, LLC, or its registered assigns (“Dominion”), in the principal amount of $600,000.00, payable in four tranches, with a Maturity Date of 3 June 2013.
The Note bears interest at the rate of ten (10%) percent per annum from 14 November until paid in full, and can be converted into common shares of the Company at a price of ten ($0.10) cents per share, subject to certain conditions to be met by the Company.
The coming days, weeks and months will reveal numerous events propelling AMBS to even greater success than that already achieved.
I know what I own and am years long AMBS
Excerpts from CEO Letter to Shareholders of November 19, 2012:
"I thank you for the trust you have placed in our management team. We fully respect the value of the money you have chosen to invest in Amarantus Biosciences, selecting us over the many other investment options available. We are focused on our mission to offer meaningful products to help patients suffering from debilitating diseases, and we believe our technologies and expertise can have an impact in multiple areas.
With the financing completed, we intend to expand our resources in the areas of corporate communications, regulatory affairs, and product development in order to execute upon our corporate strategy. In this effort, yesterday we received positive feedback at the CNS Summit 2012 on a presentation made by our Chief Scientist. We intend to continue to present the Company at various scientific and investor conferences in order to expose new investors and potential partners to the Company and its technologies.
MANF's current lead indication is Parkinson's disease, an area where we have produced very promising results. We have also achieved positive data in Traumatic Brain Injury (TBI) through our collaboration with Banyan Biomarkers. Our #C4CT program has attracted significant attention among NFL players and other professional athletes who have suffered from brain injuries, and we intend to leverage those relationships to raise awareness of MANF's potential role in TBI. In addition to Parkinson's disease and TBI, MANF has shown to be effective across a broad range of indications. The recent publication of myocardial infarction data validating a MANF-based approach has added significant value to our patent portfolio. Myocardial Infarction is a $5B market where there are currently no approved drugs to address the ischemia and reperfusion related injuries associated with heart attacks.
Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially faster than Parkinson's, Traumatic Brain Injury or Myocardial Infarction. We are evaluating the possibilities of the MANF program in various orphan disease areas through our recent grant from the Center of Excellence for Apoptosis Research and collaborations with academic labs. We expect this process to be completed within a calendar year, and we will be updating shareholders on an on-going basis regarding results of experiments as data becomes available. The key advantage to this strategy is that the Investigational New Drug (IND) protocols required for our Parkinson's program will overlap with our orphan drug program; therefore, an additional IND should be attainable in the same timeframe.
We are at a very exciting time here at Amarantus. We have secured the resources and advisors to advance our current assets and expand our business development efforts. We will implement this strategy by honing in on our core program, MANF, and finding innovative solutions to further enable MANF's development and secure Amarantus' ownership of the MANF space. We are encouraged by our data to date, and continue to believe the asset has blockbuster potential.
Your Board of Directors and management team remain dedicated to improving the lives of patients suffering from a variety of illnesses and diseases. We are motivated by the prospects of the company, and our primary focus remains: progressing our assets to help patients and increase shareholder value. I would like to personally thank each of you, and will work to ensure your trust is maintained as Amarantus grows."
I know what I own and am years long AMBS
Potential multi-billion dollar company in the making:
1) First test ever for Parkinsonism.
2) First test ever for Alzheimers disease.
3) Possible drug to cure Parkinsonism.
4) Drug to HEAL heart damage maybe up to 40% in heart attack victims.
5) Possible drug to heal stroke victims.
6) Dr. Joseph Rubinfeld, Amgen Co Founder states, "I believe in MANF. I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
I know what I own and am years long AMBS
Time relative information should not be OMITTED when trying to cite "facts."
Post #53920 states:
Amarantus retained the services of Dr. Essam Sheta, former CLIA Laboratory Director at Power3, to assist the Company in preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro® Parkinson's Disease Blood Test.
I know what I own and am years long AMBS
The A/S is for a poison pill!!
Why would management enact a poison pill? Because they feel a buyout is on the horizon.
One opinion concerning the company’s decision to enact the shareholders rights plan:
A shareholder rights plan, also known as a "poison pill", is a type of defensive tactic used by a corporation's board of directors to guard against a possible takeover attempt.
This seems to be roughly similar to declaring temporary martial law. It can help prevent against a coup attempt against the company. This company owns the rights to many valuable patents. the potential breakup value is much more than the current market price (especially after the expected release of positive test results), and therefore it is vulnerable to a hostile buyout.
This may be considered a strong positive at least in the short or medium term. They have set the expiration for this for Dec. 2013. This seems to me a reasonable period to allow the company to re-establish its share price to a healthy level, and put it visibly on a solid footing in the eyes of the public. On balance, I think this is a very good deal for shareholders for the coming year. It means we won't be prematurely bought out before this company can realize its, and its stocks more full potential.
I know what I own and am years long AMBS
Excerpts from CEO Letter to Shareholders of November 19, 2012:
"I thank you for the trust you have placed in our management team. We fully respect the value of the money you have chosen to invest in Amarantus Biosciences, selecting us over the many other investment options available. We are focused on our mission to offer meaningful products to help patients suffering from debilitating diseases, and we believe our technologies and expertise can have an impact in multiple areas.
With the financing completed, we intend to expand our resources in the areas of corporate communications, regulatory affairs, and product development in order to execute upon our corporate strategy. In this effort, yesterday we received positive feedback at the CNS Summit 2012 on a presentation made by our Chief Scientist. We intend to continue to present the Company at various scientific and investor conferences in order to expose new investors and potential partners to the Company and its technologies.
MANF's current lead indication is Parkinson's disease, an area where we have produced very promising results. We have also achieved positive data in Traumatic Brain Injury (TBI) through our collaboration with Banyan Biomarkers. Our #C4CT program has attracted significant attention among NFL players and other professional athletes who have suffered from brain injuries, and we intend to leverage those relationships to raise awareness of MANF's potential role in TBI. In addition to Parkinson's disease and TBI, MANF has shown to be effective across a broad range of indications. The recent publication of myocardial infarction data validating a MANF-based approach has added significant value to our patent portfolio. Myocardial Infarction is a $5B market where there are currently no approved drugs to address the ischemia and reperfusion related injuries associated with heart attacks.
Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially faster than Parkinson's, Traumatic Brain Injury or Myocardial Infarction. We are evaluating the possibilities of the MANF program in various orphan disease areas through our recent grant from the Center of Excellence for Apoptosis Research and collaborations with academic labs. We expect this process to be completed within a calendar year, and we will be updating shareholders on an on-going basis regarding results of experiments as data becomes available. The key advantage to this strategy is that the Investigational New Drug (IND) protocols required for our Parkinson's program will overlap with our orphan drug program; therefore, an additional IND should be attainable in the same timeframe.
We are at a very exciting time here at Amarantus. We have secured the resources and advisors to advance our current assets and expand our business development efforts. We will implement this strategy by honing in on our core program, MANF, and finding innovative solutions to further enable MANF's development and secure Amarantus' ownership of the MANF space. We are encouraged by our data to date, and continue to believe the asset has blockbuster potential.
Your Board of Directors and management team remain dedicated to improving the lives of patients suffering from a variety of illnesses and diseases. We are motivated by the prospects of the company, and our primary focus remains: progressing our assets to help patients and increase shareholder value. I would like to personally thank each of you, and will work to ensure your trust is maintained as Amarantus grows."
I know what I own and am years long AMBS
Potential multi-billion dollar company in the making:
1) First test ever for Parkinsonism.
2) First test ever for Alzheimers disease.
3) Possible drug to cure Parkinsonism.
4) Drug to HEAL heart damage maybe up to 40% in heart attack victims.
5) Possible drug to heal stroke victims.
6) Dr. Joseph Rubinfeld, Amgen Co Founder states, "I believe in MANF. I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
I know what I own and am years long AMBS
Re Dominion Capital, LLC, increasing their investment to (i.e., faith in) Amarantus.
Facts (as stated in the 1/31/13 PR):
In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000. The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed to a "no shorting" provision.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
Opinions that “undisclosed conditions” are included are baseless. For those wishing to review the facts reported in the 8-K of 11/14/12:
On 14 November 2012, Amarantus Biosciences, Inc. (the “Company”), entered into a Convertible Promissory Note with Dominion Capital, LLC, or its registered assigns (“Dominion”), in the principal amount of $600,000.00, payable in four tranches, with a Maturity Date of 3 June 2013.
The Note bears interest at the rate of ten (10%) percent per annum from 14 November until paid in full, and can be converted into common shares of the Company at a price of ten ($0.10) cents per share, subject to certain conditions to be met by the Company.
The coming days, weeks and months will reveal numerous events propelling AMBS to even greater success than that already achieved.
I know what I own and am years long AMBS
The Michael J. Fox Foundation (MJFF) does NOT invest in scams or disreputable companies. They have a comprehensive vetting process to ensure their grant monies are given to real companies and for real, viable research purposes.
Re MJFF Funding:
MJFF awards grants on THEIR schedule, not that of “investors.” With the upcoming MJFF Hot Topics Webinar on 2/19, the MJFF is preparing to provide organization updates. Click the following link for more info:
Hot Topics Webinar
I know what I own and am years long AMBS
AMBS and EVERY OTHER REAL BUSINESS IN AMERICA pay to promote their businesses and/or services. Whether advertising or promoting via newspapers, online, television, radio, phonebooks, etc., all companies pay to promote themselves.
I know what I own and am years long AMBS
Average daily shares trading volume last 7 trading days: 4.57 M
Average daily $ trading volume last 7 trading days: $408,593
Float is in the hands of knowledgeable, well-informed and patient longs who know what they own.
Daily PPS action is immaterial at these trading volume levels, regardless of any opinions.
I know what I own and am years long AMBS
Re Trading & PPS for the period 1/2/13 – 2/1/13:
Total share volume: 375,787,245 (daily average 17,081,238)
Total $ volume: $38,551,557 (daily average $1,752,344)
Total trades volume: 19054 (daily average 866)
Average shares traded/trade: 19,722
Average $ traded/trade: $2,023
Average PPS: .09804
Only 5 of 22 trading days had an average PPS above .10646.
Volume each of the past 7 days has been less than 8 M.
01/24/13 - 4,062,831
01/25/13 - 5,046,005
01/28/13 - 7,837,595
01/29/13 - 6,033,433
01/30/13 - 2,286,006
01/31/13 - 3,443,865
02/01/13 - 3,310,991
The float is all but locked up, and management has been working without compensation and also investing by buying additional shares. They are in it with each shareholder.
I know what I own and am years long AMBS
AMBS up 296% since 11/1/12. Not bad for three months, and the best is yet to come.
I know what I own and am years long AMBS
Re Investing for Future purposes:
To say that a company who invests $3M in R&D (especially in the biopharm industry) LOST the money is akin to saying:
- a person making mortgage payments LOST their money every month because they do NOT own their house, or
- a person investing in a stock/company LOST their money immediately after buying the stock because they did NOT receive an immediate payout.
Intelligent investments for future gains/benefit are not “lost” money IMO.
I know what I own and am very long AMBS
The company website and this board have LOTS of real, verifiable information on a real, quality and professionally managed company.
For those who need HELP gathering real information on a real company with professional and experienced leaders fighting a real debilitating disease, go to the company website which has an abundance of quality, factual and verifiable information.
Amarantus Bioscience, Inc.
For those who need HELP gathering real supporting documentation on a real company involved with other real companies in fighting a real debilitating disease, please visit the following websites (just to name a few):
MJFF Hot Topics Webinar of 2/19
MJFF AMBS 2010 Grant Abstract
AMBS & Banyan Biomarkers TBI Collaboration
I know what I own and am years long AMBS
Something made Dominion Capital say yes to the extra $1.4 million, and its all good IMO.
SUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital. The original $600,000 note, dated November 14, 2012, was amended to a face value of $2,000,000 before deducting placement agent fees and other offering expenses. Proceeds will be used to provide funding for Amarantus' lead asset Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), the advancement of the Company's diagnostic platforms, and for general working capital.
Do these look like typical OTC garbage?
Peer Reviewed Data
AMBS and Banyan Biomarkers
DOD $26.3 M Contract
MJFF 2010 Grant to AMBS
Isn't it amazing how all these companies/government agencies/professional organizations have been duped into buying into this "scam"? hahaha - NOT!
I know what I own and am years long AMBS
Re Dominion Capital, LLC, increasing their investment to (i.e., faith in) Amarantus.
Facts (as stated in the 1/31/13 PR):
In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000. The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed to a "no shorting" provision.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
Opinions that “undisclosed conditions” are included are baseless. For those wishing to review the facts reported in the 8-K of 11/14/12:
On 14 November 2012, Amarantus Biosciences, Inc. (the “Company”), entered into a Convertible Promissory Note with Dominion Capital, LLC, or its registered assigns (“Dominion”), in the principal amount of $600,000.00, payable in four tranches, with a Maturity Date of 3 June 2013.
The Note bears interest at the rate of ten (10%) percent per annum from 14 November until paid in full, and can be converted into common shares of the Company at a price of ten ($0.10) cents per share, subject to certain conditions to be met by the Company.
The coming days, weeks and months will reveal numerous events propelling AMBS to even greater success than that already achieved.
I know what I own and am years long AMBS
Re MJFF Funding:
MJFF awards grants on THEIR schedule, not that of “investors.” With the upcoming MJFF Hot Topics Webinar on 2/19, the MJFF is preparing to provide organization updates. Click the following link for more info:
Hot Topics Webinar
I know what I own and am years long AMBS
Re Trading & PPS for the period 1/2/13 – 2/1/13:
Total share volume: 375,787,245 (daily average 17,081,238)
Total $ volume: $38,551,557 (daily average $1,752,344)
Total trades volume: 19054 (daily average 866)
Average shares traded/trade: 19,722
Average $ traded/trade: $2,023
Average PPS: .09804
Only 5 of 22 trading days had an average PPS above .10646.
Volume each of the past 7 days has been less than 8 M.
01/24/13 - 4,062,831
01/25/13 - 5,046,005
01/28/13 - 7,837,595
01/29/13 - 6,033,433
01/30/13 - 2,286,006
01/31/13 - 3,443,865
02/01/13 - 3,310,991
The float is all but locked up, and management has been working without compensation and also investing by buying additional shares. They are in it with each shareholder.
I know what I own and am years long AMBS
Average daily shares trading volume last 7 trading days: 4.57 M
Average daily $ trading volume last 7 trading days: $408,593
Float is in the hands of knowledgeable, well-informed and patient longs who know what they own.
Daily PPS action is immaterial at these trading volume levels, regardless of any opinions.
I know what I own and am years long AMBS
Quote:
--------------------------------------------------------------------------------
Latest 10q NET LOSS NEGATIVE $2,871.643
--------------------------------------------------------------------------------
To say this is the same as saying people buying a house with a mortgage have homeowner's deficit NEGATIVE for the amount of their mortgage, therefore, they should not buy the house.
Re Investing for Future purposes (i.e., deficit NEGATIVE equity):
To say that a company who invests $3M in R&D (especially in the biopharm industry) LOST the money is akin to saying:
- a person making mortgage payments LOST their money every month because they do NOT own their house, or
- a person investing in a stock/company LOST their money immediately after buying the stock because they did NOT receive an immediate payout.
Intelligent investments for future gains/benefit are not “lost” money IMO.
I know what I own and am years long
For those having a tough time doing DD on the professional, experienced and above reproach quality of the leadership behind AMBS:
Management Team
Scientific Advisory Board
Board of Advisors
Board of Directors
I know what I own and am years long AMBS
Something made Dominion Capital say yes to the extra $1.4 million, and its all good IMO.
SUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital. The original $600,000 note, dated November 14, 2012, was amended to a face value of $2,000,000 before deducting placement agent fees and other offering expenses. Proceeds will be used to provide funding for Amarantus' lead asset Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), the advancement of the Company's diagnostic platforms, and for general working capital.
I know what I own and am years long AMBS
Some of my thoughts:
Re Trading & PPS for the period 1/2/13 – 2/1/13:
Total share volume: 375,787,245 (daily average 17,081,238)
Total $ volume: $38,551,557 (daily average $1,752,344)
Total trades volume: 19054 (daily average 866)
Average shares traded/trade: 19,722
Average $ traded/trade: $2,023
Average PPS: .09804
Only 5 of 22 trading days had an average PPS above .10646.
Volume each of the past 7 days has been less than 8 M.
01/24/13 - 4,062,831
01/25/13 - 5,046,005
01/28/13 - 7,837,595
01/29/13 - 6,033,433
01/30/13 - 2,286,006
01/31/13 - 3,443,865
02/01/13 - 3,310,991
The float is all but locked up, and management has been working without compensation and also investing by buying additional shares. They are in it with each shareholder.
Re Investing for Future purposes:
To say that a company who invests $3M in R&D (especially in the biopharm industry) LOST the money is akin to saying:
- a person making mortgage payments LOST their money every month because they do NOT own their house, or
- a person investing in a stock/company LOST their money immediately after buying the stock because they did NOT receive an immediate payout.
Intelligent investments for future gains/benefit are not “lost” money IMO.
Re MJFF Funding:
MJFF awards grants on THEIR schedule, not that of “investors.” With the upcoming MJFF Hot Topics Webinar on 2/19, the MJFF is preparing to provide organization updates. Click the following link for more info:
Hot Topics Webinar
Re Dominion Capital, LLC, increasing their investment to (i.e., faith in) Amarantus.
Facts (as stated in the 1/31/13 PR):
In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000. The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed to a "no shorting" provision.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
Opinions that “undisclosed conditions” are included are baseless. For those wishing to review the facts reported in the 8-K of 11/14/12:
On 14 November 2012, Amarantus Biosciences, Inc. (the “Company”), entered into a Convertible Promissory Note with Dominion Capital, LLC, or its registered assigns (“Dominion”), in the principal amount of $600,000.00, payable in four tranches, with a Maturity Date of 3 June 2013.
The Note bears interest at the rate of ten (10%) percent per annum from 14 November until paid in full, and can be converted into common shares of the Company at a price of ten ($0.10) cents per share, subject to certain conditions to be met by the Company.
The coming days, weeks and months will reveal numerous events propelling AMBS to even greater success than that already achieved.
I know what I own and am years long AMBS
Do these look like typical OTC garbage?
http://ir.stockpr.com/amarantus/company-news/detail/523/amarantus-bioscience-announces-publication-of-independent-peer-reviewed-data-for-receptor-and-secretion-pathways-related-to-manf
http://www.businesswire.com/news/home/20111122005486/en/Amarantus-Biosciences-Banyan-Biomarkers-Announce-Traumatic-Brain
http://www.businesswire.com/news/home/20101005005193/en/Banyan-Biomarkers-Awarded-26.3-Million-Department-Defense
Isn't it amazing how all these companies/government agencies/professional organizations have been duped into buying into this "scam"? hahaha - NOT!
I know what I own and am years long AMBS
Something made Dominion Capital say yes to the extra $1.4 million, and its all good IMO.
SUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital. The original $600,000 note, dated November 14, 2012, was amended to a face value of $2,000,000 before deducting placement agent fees and other offering expenses. Proceeds will be used to provide funding for Amarantus' lead asset Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), the advancement of the Company's diagnostic platforms, and for general working capital.
I know what I own and am years long AMBS
Thank you for your "insightful" contribution.
Potential multi-billion dollar company in the making:
1) First test ever for Parkinsonism.
2) First test ever for Alzheimers disease.
3) Possible drug to cure Parkinsonism.
4) Drug to HEAL heart damage maybe up to 40% in heart attack victims.
5) Possible drug to heal stroke victims.
6) Dr. Joseph Rubinfeld, Amgen Co Founder states, "I believe in MANF. I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
I know what I own and am years long AMBS